Current Report Filing (8-k)
August 17 2017 - 4:18PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 14, 2017
IMMUNOCELLULAR THERAPEUTICS, LTD.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35560
|
|
93-1301885
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
23622 Calabasas Road,
Suite 300
Calabasas,
California 91302
|
|
|
|
|
(Address of Principal Executive Offices)
(Zip Code)
|
|
|
Registrants telephone number, including area code: (818) 264-2300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On August 14, 2017, ImmunoCellular Therapeutics, Ltd. (the Company) issued a press release announcing financial results for
the quarter ended June 30, 2017. A copy of this press release is attached as Exhibit 99.1.
This information, including exhibits
attached hereto and the information under item 9.01 below, shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Press Release, dated August 14, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: August 17, 2017
|
|
|
|
IMMUNOCELLULAR THERAPEUTICS, LTD.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ David Fractor
|
|
|
|
|
|
|
David Fractor
|
|
|
|
|
|
|
Chief Financial Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Press Release, dated August 14, 2017
|
EOM Pharmaceutical (PK) (USOTC:IMUC)
Historical Stock Chart
From Aug 2024 to Sep 2024
EOM Pharmaceutical (PK) (USOTC:IMUC)
Historical Stock Chart
From Sep 2023 to Sep 2024